Therapy of cutaneous human Papillomavirus infections

Dermatologic Therapy

Volumn 17, Issue 6, 2004, Pages 441-448

  Rivera, Allison ^a   Tyring, Stephen K ^a,b  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b University of Texas Health Science Center at Houston   (United States)

Author keywords

Human Papillomavirus; Therapy; Treatment

Indexed keywords

ALPHA INTERFERON; BETA INTERFERON; BLEOMYCIN; CANTHARIDIN; CHLOROACETIC ACID; CIDOFOVIR; DICHLOROACETIC ACID; FLUOROURACIL; FORMALDEHYDE; GAMMA INTERFERON; GLUTARALDEHYDE; IMIQUIMOD; IMMUNOMODULATING AGENT; INTERFERON; PODOPHYLLIN; PODOPHYLLOTOXIN; RETINOID; SALICYLIC ACID; TRICHLOROACETIC ACID; VIRUS VACCINE;

AGE DISTRIBUTION; ANTIVIRAL ACTIVITY; BURNING SENSATION; CAUTERIZATION; CHILL; CLINICAL TRIAL; COMA; CONTACT SENSITIZATION; CRYOTHERAPY; CURETTAGE; CYTOPENIA; DESQUAMATION; DIARRHEA; DOSE RESPONSE; DRUG CLEARANCE; DRUG EFFICACY; DRUG SAFETY; ERYTHEMA; FATIGUE; FEVER; FLU LIKE SYNDROME; HEADACHE; HUMAN; HYPOKALEMIA; HYPOTENSION; INJECTION PAIN; LASER SURGERY; LOW LEVEL LASER THERAPY; MYALGIA; NAIL DYSTROPHY; NAUSEA; PERIPHERAL NEUROPATHY; PRURITUS; RASH; RAYNAUD PHENOMENON; RECURRENCE RISK; REVIEW; SEX ROLE; SIDE EFFECT; SKIN EDEMA; SKIN IRRITATION; SKIN ULCER; SURGICAL TECHNIQUE; VERRUCA VULGARIS; VIRUS INFECTION; VIRUS TRANSMISSION; VOMITING; WART VIRUS;

HUMANS; IMMUNOLOGIC FACTORS; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS;

EID: 10644264339     PISSN: 13960296     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1396-0296.2004.04047.x     Document Type: Review

References (55)

1. Severson J, Evans TY, Lee P, Chan T, Arany I, Tyring SK. Human Papillomavirus infections: epidemiology, pathogenesis, and therapy. J Cutan Med Surg 2001: 5: 43-60.
2. Czelusta A, Evans T, Arany I, Tyring S. A guide to immunotherapy of genital warts. Biodrugs 1999: 11: 319-332.
3. McDonald LL, Stites PC, Buntin DM. Sexually-transmitted diseases update. Dermatol Clin 1997: 15: 221-232.
4. Centers for Disease Control and Prevention. Sexually Transmitted Disease Guidelines 2002. MMWR Recomm Report 2002: 51: 1-80.
5. Brown TJ, Yen-Moore A, Tyring SK. An overview of sexually-transmitted diseases. Part II. J Am Acad Dermatol 1999: 41: 661-677, quiz 678-680.
6. Edwards A, Atma-Ram A, Thin RN. Podophyllotoxin 0.5% versus podophyllin 20% to treat penile warts. Genitourin Med 1988: 64: 263-265.
7. Frazer P, Lacey C. Podophyllotoxin is superior to podophyllin in the treatment of genital warts. J Eur Acad Venereol 1993: 2: 328-334.
8. Jablonska S. Traditional therapies for the treatment of condylomata acuminata (genital warts). Australas J Dermatol 1998: 39 (Suppl. 1): S2-S4.
9. Kinghorn GR, McMillan A, Mulcahy F, Drake S, Lacey C, Bingham JS. An open, comparative, study of the efficacy of 0.5% podophyllotoxin lotion and 25% podophyllotoxin solution in the treatment of condylomata acuminata in males and females. Int J STD AIDS 1993: 4: 194-199.
10. Syed TA, Cheema KM, Khayyami M, Ahmad SA, Ahmad SH, Ahmad S. Human leukocyte interferon-alpha versus podophyllotoxin in cream for the treatment of genital warts in males. A placebo-controlled, double-blind, comparative study. Dermatology 1995: 191: 129-132.
11. Godley MJ, Bradbeer CS, Gellan M, Thin RN. Cryotherapy compared with trichloroacetic acid in treating genital warts. Genitourin Med 1987: 63: 390-392.
12. Krebs HB. The use of topical 5-fluorouracil in the treatment of genital condylomas. Obstet Gynecol Clin North Am 1987: 14: 559-568.
13. Pride GL. Treatment of large lower genital tract condylomata acuminata with topical 5-fluorouracil. J Reprod Med 1990: 35: 384-387.
14. 2 laser for treatment of vaginal condylomata. Obstet Gynecol 1984: 64: 773-778.
15. Goodman A, Zukerberg LR, Nikrui N, Scully RE. Vaginal adenosis and clear cell carcinoma after 5-fluorouracil treatment for condylomas. Cancer 1991: 68: 1628-1632.
16. Swinehart JM, Skinner RB, McCarty JM et al. Development of intralesional therapy with fluorouracil/adrenaline injectable gel for management of condylomata acuminata: two phase II clinical studies. Genitourin Med 1997: 73: 481-487.
17. Swinehart JM, Sperling M, Phillips S et al. Intralesional fluorouracil/epinephrine injectable gel for treatment of condylomata acuminata. A phase 3 clinical study. Arch Dermatol 1997: 133: 67-73.
18. Shelley WB, Shelley ED. Intralesional bleomycin sulfate therapy for warts. A novel bifurcated needle puncture technique. Arch Dermatol 1991: 127: 234-236.
19. Munn SE, Higgins E, Marshall M, Clement M. A new method of intralesional bleomycin therapy in the treatment of recalcitrant warts. Br J Dermatol 1996: 135: 969-971.
20. Miller RA. Nail dystrophy following intralesional injections of bleomycin for a periungual wart. Arch Dermatol 1984: 120: 963-964.
21. Menter A, Black-Noller G, Riendeau LA, Monti KL. The use of EMLA cream and 1% lidocaine infiltration in men for relief of pain associated with the removal of genital warts by cryotherapy. J Am Acad Dermatol 1997: 37: 96-100.
22. 2 laser-generated plume of smoke and its consequences to the surgeon. Obstet Gynecol 1990: 75: 114-118.
23. Ferenczy A, Bergeron C, Richart RM. Carbon dioxide laser energy disperses human Papillomavirus deoxyribonucleic acid onto treatment fields. Am J Obstet Gynecol 1990: 163: 1271-1274.
24. Gloster HM Jr, Roenigk RK. Risk of acquiring human Papillomavirus from the plume produced by the carbon dioxide laser in the treatment of warts. J Am Acad Dermatol 1995: 32: 436-441.
25. Hughes PS, Hughes AP. Absence of human Papillomavirus DNA in the plume of erbium: YAG laser-treated warts. J Am Acad Dermatol 1998: 38: 426-428.
26. Bergman A, Nalick R. Genital human Papillomavirus infection in men. Diagnosis and treatment with a laser and 5-fluorouracil. J Reprod Med 1991: 36: 363-366.
27. Ferenczy A. Laser treatment of genital human Papillomavirus infections in the male patient. Obstet Gynecol Clin North Am 1991: 18: 525-535.
28. von Krogh G. Management of anogenital warts (condylomata acuminata). Eur J Dermatol 2001: 11: 598-603; quiz 604.
29. Bornstein J, Pascal B, Zarfati D, Goldshmid N, Abramovici H. Recombinant human interferon-beta for condylomata acuminata: a randomized, double-blind, placebo-controlled study of intralesional therapy. Int J STD AIDS 1997: 8: 614-621.
30. Eron LJ, Judson F, Tucker S et al. Interferon therapy for condylomata acuminata. N Engl J Med 1986: 315: 1059-1064.
31. Friedman-Kien A. Management of condylomata acuminata with Alferon N injection, Interferon alfa-n3 (human leukocyte derived). Am J Obstet Gynecol 1995: 172: 1359-1368.
32. Friedman-Kien AE, Eron LJ, Conant M et al. Natural interferon alfa for treatment of condylomata acuminata. Jama 1988: 259: 533-538.
33. Monsonego J, Cessot G, Ince SE, Galazka AR, Abdul-Ahad AK. Randomized double-blind trial of recombinant interferon-beta for condyloma acuminatum. Genitourin Med 1996: 72: 111-114.
34. Reichman RC, Micha JP, Weck PK et al. Interferon alpha-n1 (Wellferon) for refractory genital warts: efficacy and tolerance of low dose systemic therapy. Antiviral Res 1988: 10: 41-57.
35. Vance JC, Bart BJ, Hansen RC et al. Intralesional recombinant alpha-2 interferon for the treatment of patients with condyloma acuminatum or verruca plantaris. Arch Dermatol 1986: 122: 272-277.
36. Welander CE, Homesley HD, Smiles KA, Peets EA. Intra-lesional interferon alpha-2b for the treatment of genital warts. Am J Obstet Gynecol 1990: 162: 348-354.
37. Eedy DJ. Imiquimod: a potential role in dermatology? Br J Dermatol 2002: 147: 1-6.
38. Hemmi H, Kaisho T, Takeuchi O et al. Small antiviral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway. Nat Immunol 2002: 3: 196-200.
39. Miller RL, Gerster JF, Owens ML, Slade HB, Tomai MA. Imiquimod applied topically: a novel immune response modifier and new class of drug. Int J Immunopharmacol 1999: 21: 1-14.
40. Kono T, Kondo S, Pastore S et al. Effects of a novel topical immunomodulator, imiquimod, on keratinocyte cytokine gene expression. Lymphokine Cytokine Res 1994: 13: 71-76.
41. Hengge UR, Cusini M. Topical immunomodulators for the treatment of external genital warts, cutaneous warts and molluscum contagiosum. Br J Dermatol 2003: 149 (Suppl. 66): 15-19.
42. Garland SM, Sellors JW, Wikstrom A et al. Imiquimod 5% cream is a safe and effective self-applied treatment for anogenital warts - results of an open-label, multicentre Phase IIIB trial. Int J STD AIDS 2001: 12: 722-729.
43. Edwards L, Ferenczy A, Eron L et al. Self-administered topical 5% imiquimod cream for external anogenital warts. HPV Study Group Human Papillomavirus Arch Dermatol 1998: 134: 25-30.
44. Beutner KR, Spruance SL, Hougham AJ, Fox TL, Owens ML, Douglas JM Jr. Treatment of genital warts with an immune-response modifier (imiquimod). J Am Acad Dermatol 1998: 38: 230-239.
45. Beutner KR, Tyring SK, Trofatter KF Jr et al. Imiquimod, a patient-applied immune-response modifier for treatment of external genital warts. Antimicrob Agents Chemother 1998: 42: 789-794.
46. Edwards L. Imiquimod in clinical practice. Australas J Dermatol 1998: 39 (Suppl. 1): S14-S16.
47. Gilson RJ, Shupack JL, Friedman-Kien AE et al. A randomized, controlled, safety study using imiquimod for the topical treatment of anogenital warts in HIV-infected patients. Imiquimod Study Group Aids 1999: 13: 2397-2404.
48. Goldstein D, Hertzog P, Tomkinson E et al. Administration of imiquimod, an interferon inducer, in asymptomatic human immunodeficiency virus-infected persons to determine safety and biologic response modification. J Infect Dis 1998: 178: 858-861.
49. Snoeck R, Andrei G, De Clercq E. Cidofovir in the treatment of HPV-associated lesions. Verh K Acad Geneeskd Belg 2001: 63: 93-120, discussion 120-122.
50. Tyring S, Douglas J, Corey L. A phase I/II study of cidofovir gel for refractory condyloma acuminatum in patients with HIV infection (poster 296). 55th Annual Meeting of Dermatology. San Francisco, CA, 1997.
51. Snoeck R, Bossens M, Parent D et al. Phase II double-blind, placebo-controlled study of the safety and efficacy of cidofovir topical gel for the treatment of patients with human Papillomavirus infection. Clin Infect Dis 2001: 33: 597-602.
52. Zabawski EJ Jr, Cockerell CJ. Topical and intralesional cidofovir: a review of pharmacology and therapeutic effects. J Am Acad Dermatol 1998: 39: 741-745.
53. Snoeck R, Noel JC, Muller C, De Clercq E, Bossens M. Cidofovir, a new approach for the treatment of cervix intraepithelial neoplasia grade III (CIN III). J Med Virol 2000: 60: 205-209.
54. Koutsky LA, Ault KA, Wheeler CM, et al. A controlled trial of human Papillomavirus type 16 vaccine. N Engl J Med 2002: 347: 1645-1651.
55. Fife KH. Human Papillomavirus vaccine development. Australas J Dermatol 1998: 39 (Suppl. 1): S8-S10.